Neoadjuvant · Randomized phase II; N=110 locally advanced dMMR/MSI-H CRC. Toripalimab+celecoxib vs toripalimab alone for 12 cycles. Primary endpoint centrally reviewed pCR. · pCR 89% (49/55) vs 69% (38/55)

PICC-2

Clinical question: Does adding celecoxib to neoadjuvant toripalimab improve pCR in locally advanced dMMR/MSI-H colorectal cancer?

pCR 89% (49/55) vs 69% (38/55); absolute gain ~20 points; P=0.014; NNT 5. Median follow-up 18.1 months. · Registry:

Design, population and treatment

Randomized phase II; N=110 locally advanced dMMR/MSI-H CRC. Toripalimab+celecoxib vs toripalimab alone for 12 cycles. Primary endpoint centrally reviewed pCR.

Key efficacy outcome

89 · intervention

89 · comparator

NNT 5 for one additional pCR; comparative grade-specific toxicity not calculated.

Grade-specific toxicity not present in retrieved abstract excerpt; no toxicity rate inferred.

Safety and absolute effect

pCR rate (%)

https://www.sciencedirect.com/science/article/pii/S1470204526002202

Interpretation and limitations

Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.

Primary source

Primary publication · DOI: 10.1016/S1470-2045(26)00220-2